Incyte's JAK1/JAK2 inhibitor ruxolitinib cream treats atopic dermatitis in phase II clinical success

Incyte's JAK1/JAK2 inhibitor ruxolitinib's local cream struck the primary and secondary endpoints of the Stage III TRuE-AD1 trial in adolescents and adults with mild to moderate asymptomatic dermatitisThe local cream of ruxolitinib also reached its main endpoint in the Phase III TRuE-AD2 studyJim Lee, head of the company's inflammation and auto
immunologydivision, commented: "The successful results of both studies confirm the potential of ruxolitinib cream, as a nonsteroidal drug, to treat millions of patients with ectopic dermatitisWe look forward to working with regulators to seek approval of ruxolitinib cream as the first local drug preparation for JAK inhibitorsTRuE-AD1 included 622 patients aged 12 and over who werediagnosed withhad aspecificty dermatitis for at least two yearsPatients were randomly assigned to receive ruxolitinib cream twice a dayin TRuE-AD1, 50 percent of patients receiving low-dose ruxolitinib cream scored IGA-TS, and 53.8 percent of patients who received high doses reached IGA-TS, compared with 15.1 percent in the control groupIn addition, 56% and 62.1% of patients in the low-dose and high-dose ruxolitinib cream group reached EASI75, respectively, compared with 24.6% in the control group